UNSPSC 51343806: Lamivudine/zidovudine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

UNSPSC 51343806 Lamivudine/zidovudine is a Commodity code that in recent state and local procurement shows minimal alignment with its nominal scope. The two most recent opportunities posted under this code are a completed pharmaceutical warehouse piggyback award by the Illinois Department of Public Health for Doxycycline Hyclate and Ciprofloxacin Hydrochloride (neither of which are lamivudine or zidovudine), and a Seminole County, Florida procurement for Naloxone and Safe Drug Deactivation Systems — also unrelated to the code's stated product. The mismatch suggests either miscoding at the issuing body, miscategorization in the opportunity feed, or that state and local health agencies are using this Commodity code to capture a broader class of pharmaceutical procurement than the code's name indicates.

The recent activity spans at least two states — Illinois and Florida — with issuing bodies consisting of a state health department and a county health authority, both sourcing through open competitive processes (an Invitation for Bid and an IFB, respectively). The Illinois contract, posted August 28, 2026, was awarded to Chartwell Rx LLC for $2.999999 million over 12 months plus two renewal options; Seminole County posted its Naloxone and deactivation-systems IFB on June 30, 2026, with a response deadline of July 26, 2023 (a date error in the source suggests this is an older, archived record). The code shows limited recent activity relevant to its stated pharmaceutical product line, and pursuit should be evaluated based on whether your firm's actual capability aligns with the products state and local agencies are currently sourcing under it.